The Experts below are selected from a list of 324 Experts worldwide ranked by ideXlab platform
Vernon Hartz - One of the best experts on this subject based on the ideXlab platform.
-
Effect of Reproducibility of Baseline Arrhythmia Induction on Drug Efficacy Predictions and Outcome in the Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM) Trial
The American journal of cardiology, 1997Co-Authors: David E. Mann, Elizabeth A. Hahn, Vernon Hartz, Michael J. ReiterAbstract:Spontaneous variability over time in the ease of induction of ventricular arrhythmias may mimic a Drug effect and affect the predictive value of Drug therapy guided by programmed stimulation. We assessed the effect of baseline reproducibility of arrhythmia induction on the incidence and accuracy of Drug Efficacy predictions in the Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM) trial. Patients with sustained ventricular tachyarrhythmias induced twice during baseline electrophysiologic testing with the same stimulation technique, i.e., induced at the same pacing site with the same drive cycle length and number of extrastimuli, were identified from the ESVEM database. These patients with highly reproducible arrhythmia induction were compared to those with less reproducible arrhythmias. Of 473 randomized patients with reproducibility data, 313 (66%) had highly reproducible arrhythmias. In patients randomized to electrophysiologic testing, baseline arrhythmia reproducibility did not affect the incidence of Drug Efficacy predictions (70 of 157 [45%], Drug Efficacy predictions in patients with highly reproducible arrhythmias vs 34 of 79 [43%] with less reproducible arrhythmias, p = 0.890). Drug Efficacy predictions obtained by electrophysiologic testing in patients with highly reproducible arrhythmias were not associated with decreases in arrhythmia recurrence (p = 0.202), all-cause mortality (p = 0.301), cardiac death (p = 0.358), or arrhythmic death (p = 0.307) compared to those with less reproducible arrhythmias. Analysis of patients with highly reproducible sustained monomorphic ventricular tachycardia led to similar results. In the ESVEM trial, most patients had highly reproducible arrhythmia induction during baseline electrophysiologic testing. Reproducibility of arrhythmia induction in the baseline state had no effect on the incidence or accuracy of Drug Efficacy predictions.
-
Reproducibility of Drug Efficacy Predictions by Holter Monitoring in the Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM) Trial
The American journal of cardiology, 1997Co-Authors: Michael J. Reiter, Labros A. Karagounis, David E. Mann, James A. Reiffel, Elizabeth A. Hahn, Vernon HartzAbstract:Selection of antiarrhythmic therapy may be based on suppression of spontaneous ventricular arrhythmias assessed by Holter monitoring, but the implications of discordant Holter results on repeat 24-hour monitoring has not been defined. This study examines the frequency and significance of reproducible Holter suppression on two 24-hour recordings in the Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM) trial. Repeat 24-hour Holter monitoring was obtained in patients randomized to the Holter monitor limb of the ESVEM trial, during the same hospitalization, after a Drug Efficacy prediction. These Holters were not used to define Drug Efficacy but were subsequently analyzed to determine the reproducibility of Drug Efficacy predictions by Holter monitoring. A repeat 24-hour Holter monitor, following the one that predicted Drug Efficacy, was available in 119 patients. Ninety-nine patients (83%) also had suppression that met Efficacy criteria on the second Holter monitor. There were no significant differences in arrhythmia recurrence (p = 0.612) or mortality (p = 0.638) in patients with concordant Holter results (n = 99; 1-year arrhythmia recurrence = 45%; 1-year mortality = 10%) compared with those with discordant Holter results (n = 20; 1-year arrhythmia recurrence = 45%; 1-year mortality = 16%). We conclude that (1) there is discordance between the first effective Holter monitor and a repeat Holter monitor in 17% of patients, and (2) suppression of ventricular ectopic activity on 2 separate 24-hour Holter monitors does not identify a group with a better outcome, nor does failure of suppression on the second Holter monitor identify a group with a worse prognosis.
-
Significance and Incidence of Concordance of Drug Efficacy Predictions by Holter Monitoring and Electrophysiological Study in the ESVEM Trial
Circulation, 1995Co-Authors: Michael J. Reiter, David E. Mann, James A. Reiffel, Elizabeth Hahn, Vernon HartzAbstract:Background Selection of antiarrhythmic therapy may be based on either suppression of spontaneous ventricular arrhythmias assessed by Holter monitoring or by suppression of inducible ventricular arrhythmias during electrophysiological study. This study examines the frequency and significance of concordance of these two approaches in the Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM) trial. Methods and Results Twenty-four-hour Holter monitoring was performed in patients randomized to the electrophysiology limb of the ESVEM study at the time of the first Drug trial and at the time of an effective Drug trial. Holter monitors were available in 65% (146/226) of patients at the time of the first Drug trial and in 93% (100/108) of patients at the time of an electrophysiology study predicting Drug Efficacy. There were no clinical differences between patients who had and those who did not have a Holter monitor. At the time of the first Drug trial, concordance of Holter and electrophysiological predictions of Drug Efficacy was observed in 46% of patients (both techniques predicted Efficacy in 23%; neither predicted Efficacy in 23%). Discordant results were observed in 54% (Holter suppression without electrophysiological suppression in 44%; electrophysiological suppression without Holter suppression in 10%). At the time of an electrophysiology study predicting Drug Efficacy, 68 of the 100 patients without inducible ventricular tachyarrhythmias also had suppression of spontaneous ventricular arrhythmias on the Holter recorded at the time of the electrophysiological study. Neither arrhythmia recurrence nor mortality was significantly different in patients with suppression of both inducible and spontaneous ventricular arrhythmias compared with those with only suppression of inducible arrhythmias. Comparison of patients with suppression of both inducible and spontaneous ventricular arrhythmias with the 188 patients in the Holter limb, in whom Efficacy was predicted by Holter monitoring only, revealed no difference in outcome. Conclusions In this population, (1) there is frequent discordance in prediction of Drug Efficacy and inEfficacy between electrophysiological study and Holter monitoring; (2) a requirement to fulfill both Holter and electrophysiological Efficacy criteria reduces the number of patients with an Efficacy prediction; and (3) suppression of both spontaneous ventricular ectopy and inducible ventricular tachyarrhythmias does not identify a group with better outcome.
Michael J. Reiter - One of the best experts on this subject based on the ideXlab platform.
-
Effect of Reproducibility of Baseline Arrhythmia Induction on Drug Efficacy Predictions and Outcome in the Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM) Trial
The American journal of cardiology, 1997Co-Authors: David E. Mann, Elizabeth A. Hahn, Vernon Hartz, Michael J. ReiterAbstract:Spontaneous variability over time in the ease of induction of ventricular arrhythmias may mimic a Drug effect and affect the predictive value of Drug therapy guided by programmed stimulation. We assessed the effect of baseline reproducibility of arrhythmia induction on the incidence and accuracy of Drug Efficacy predictions in the Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM) trial. Patients with sustained ventricular tachyarrhythmias induced twice during baseline electrophysiologic testing with the same stimulation technique, i.e., induced at the same pacing site with the same drive cycle length and number of extrastimuli, were identified from the ESVEM database. These patients with highly reproducible arrhythmia induction were compared to those with less reproducible arrhythmias. Of 473 randomized patients with reproducibility data, 313 (66%) had highly reproducible arrhythmias. In patients randomized to electrophysiologic testing, baseline arrhythmia reproducibility did not affect the incidence of Drug Efficacy predictions (70 of 157 [45%], Drug Efficacy predictions in patients with highly reproducible arrhythmias vs 34 of 79 [43%] with less reproducible arrhythmias, p = 0.890). Drug Efficacy predictions obtained by electrophysiologic testing in patients with highly reproducible arrhythmias were not associated with decreases in arrhythmia recurrence (p = 0.202), all-cause mortality (p = 0.301), cardiac death (p = 0.358), or arrhythmic death (p = 0.307) compared to those with less reproducible arrhythmias. Analysis of patients with highly reproducible sustained monomorphic ventricular tachycardia led to similar results. In the ESVEM trial, most patients had highly reproducible arrhythmia induction during baseline electrophysiologic testing. Reproducibility of arrhythmia induction in the baseline state had no effect on the incidence or accuracy of Drug Efficacy predictions.
-
Reproducibility of Drug Efficacy Predictions by Holter Monitoring in the Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM) Trial
The American journal of cardiology, 1997Co-Authors: Michael J. Reiter, Labros A. Karagounis, David E. Mann, James A. Reiffel, Elizabeth A. Hahn, Vernon HartzAbstract:Selection of antiarrhythmic therapy may be based on suppression of spontaneous ventricular arrhythmias assessed by Holter monitoring, but the implications of discordant Holter results on repeat 24-hour monitoring has not been defined. This study examines the frequency and significance of reproducible Holter suppression on two 24-hour recordings in the Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM) trial. Repeat 24-hour Holter monitoring was obtained in patients randomized to the Holter monitor limb of the ESVEM trial, during the same hospitalization, after a Drug Efficacy prediction. These Holters were not used to define Drug Efficacy but were subsequently analyzed to determine the reproducibility of Drug Efficacy predictions by Holter monitoring. A repeat 24-hour Holter monitor, following the one that predicted Drug Efficacy, was available in 119 patients. Ninety-nine patients (83%) also had suppression that met Efficacy criteria on the second Holter monitor. There were no significant differences in arrhythmia recurrence (p = 0.612) or mortality (p = 0.638) in patients with concordant Holter results (n = 99; 1-year arrhythmia recurrence = 45%; 1-year mortality = 10%) compared with those with discordant Holter results (n = 20; 1-year arrhythmia recurrence = 45%; 1-year mortality = 16%). We conclude that (1) there is discordance between the first effective Holter monitor and a repeat Holter monitor in 17% of patients, and (2) suppression of ventricular ectopic activity on 2 separate 24-hour Holter monitors does not identify a group with a better outcome, nor does failure of suppression on the second Holter monitor identify a group with a worse prognosis.
-
Significance and Incidence of Concordance of Drug Efficacy Predictions by Holter Monitoring and Electrophysiological Study in the ESVEM Trial
Circulation, 1995Co-Authors: Michael J. Reiter, David E. Mann, James A. Reiffel, Elizabeth Hahn, Vernon HartzAbstract:Background Selection of antiarrhythmic therapy may be based on either suppression of spontaneous ventricular arrhythmias assessed by Holter monitoring or by suppression of inducible ventricular arrhythmias during electrophysiological study. This study examines the frequency and significance of concordance of these two approaches in the Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM) trial. Methods and Results Twenty-four-hour Holter monitoring was performed in patients randomized to the electrophysiology limb of the ESVEM study at the time of the first Drug trial and at the time of an effective Drug trial. Holter monitors were available in 65% (146/226) of patients at the time of the first Drug trial and in 93% (100/108) of patients at the time of an electrophysiology study predicting Drug Efficacy. There were no clinical differences between patients who had and those who did not have a Holter monitor. At the time of the first Drug trial, concordance of Holter and electrophysiological predictions of Drug Efficacy was observed in 46% of patients (both techniques predicted Efficacy in 23%; neither predicted Efficacy in 23%). Discordant results were observed in 54% (Holter suppression without electrophysiological suppression in 44%; electrophysiological suppression without Holter suppression in 10%). At the time of an electrophysiology study predicting Drug Efficacy, 68 of the 100 patients without inducible ventricular tachyarrhythmias also had suppression of spontaneous ventricular arrhythmias on the Holter recorded at the time of the electrophysiological study. Neither arrhythmia recurrence nor mortality was significantly different in patients with suppression of both inducible and spontaneous ventricular arrhythmias compared with those with only suppression of inducible arrhythmias. Comparison of patients with suppression of both inducible and spontaneous ventricular arrhythmias with the 188 patients in the Holter limb, in whom Efficacy was predicted by Holter monitoring only, revealed no difference in outcome. Conclusions In this population, (1) there is frequent discordance in prediction of Drug Efficacy and inEfficacy between electrophysiological study and Holter monitoring; (2) a requirement to fulfill both Holter and electrophysiological Efficacy criteria reduces the number of patients with an Efficacy prediction; and (3) suppression of both spontaneous ventricular ectopy and inducible ventricular tachyarrhythmias does not identify a group with better outcome.
David E. Mann - One of the best experts on this subject based on the ideXlab platform.
-
Effect of Reproducibility of Baseline Arrhythmia Induction on Drug Efficacy Predictions and Outcome in the Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM) Trial
The American journal of cardiology, 1997Co-Authors: David E. Mann, Elizabeth A. Hahn, Vernon Hartz, Michael J. ReiterAbstract:Spontaneous variability over time in the ease of induction of ventricular arrhythmias may mimic a Drug effect and affect the predictive value of Drug therapy guided by programmed stimulation. We assessed the effect of baseline reproducibility of arrhythmia induction on the incidence and accuracy of Drug Efficacy predictions in the Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM) trial. Patients with sustained ventricular tachyarrhythmias induced twice during baseline electrophysiologic testing with the same stimulation technique, i.e., induced at the same pacing site with the same drive cycle length and number of extrastimuli, were identified from the ESVEM database. These patients with highly reproducible arrhythmia induction were compared to those with less reproducible arrhythmias. Of 473 randomized patients with reproducibility data, 313 (66%) had highly reproducible arrhythmias. In patients randomized to electrophysiologic testing, baseline arrhythmia reproducibility did not affect the incidence of Drug Efficacy predictions (70 of 157 [45%], Drug Efficacy predictions in patients with highly reproducible arrhythmias vs 34 of 79 [43%] with less reproducible arrhythmias, p = 0.890). Drug Efficacy predictions obtained by electrophysiologic testing in patients with highly reproducible arrhythmias were not associated with decreases in arrhythmia recurrence (p = 0.202), all-cause mortality (p = 0.301), cardiac death (p = 0.358), or arrhythmic death (p = 0.307) compared to those with less reproducible arrhythmias. Analysis of patients with highly reproducible sustained monomorphic ventricular tachycardia led to similar results. In the ESVEM trial, most patients had highly reproducible arrhythmia induction during baseline electrophysiologic testing. Reproducibility of arrhythmia induction in the baseline state had no effect on the incidence or accuracy of Drug Efficacy predictions.
-
Reproducibility of Drug Efficacy Predictions by Holter Monitoring in the Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM) Trial
The American journal of cardiology, 1997Co-Authors: Michael J. Reiter, Labros A. Karagounis, David E. Mann, James A. Reiffel, Elizabeth A. Hahn, Vernon HartzAbstract:Selection of antiarrhythmic therapy may be based on suppression of spontaneous ventricular arrhythmias assessed by Holter monitoring, but the implications of discordant Holter results on repeat 24-hour monitoring has not been defined. This study examines the frequency and significance of reproducible Holter suppression on two 24-hour recordings in the Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM) trial. Repeat 24-hour Holter monitoring was obtained in patients randomized to the Holter monitor limb of the ESVEM trial, during the same hospitalization, after a Drug Efficacy prediction. These Holters were not used to define Drug Efficacy but were subsequently analyzed to determine the reproducibility of Drug Efficacy predictions by Holter monitoring. A repeat 24-hour Holter monitor, following the one that predicted Drug Efficacy, was available in 119 patients. Ninety-nine patients (83%) also had suppression that met Efficacy criteria on the second Holter monitor. There were no significant differences in arrhythmia recurrence (p = 0.612) or mortality (p = 0.638) in patients with concordant Holter results (n = 99; 1-year arrhythmia recurrence = 45%; 1-year mortality = 10%) compared with those with discordant Holter results (n = 20; 1-year arrhythmia recurrence = 45%; 1-year mortality = 16%). We conclude that (1) there is discordance between the first effective Holter monitor and a repeat Holter monitor in 17% of patients, and (2) suppression of ventricular ectopic activity on 2 separate 24-hour Holter monitors does not identify a group with a better outcome, nor does failure of suppression on the second Holter monitor identify a group with a worse prognosis.
-
Significance and Incidence of Concordance of Drug Efficacy Predictions by Holter Monitoring and Electrophysiological Study in the ESVEM Trial
Circulation, 1995Co-Authors: Michael J. Reiter, David E. Mann, James A. Reiffel, Elizabeth Hahn, Vernon HartzAbstract:Background Selection of antiarrhythmic therapy may be based on either suppression of spontaneous ventricular arrhythmias assessed by Holter monitoring or by suppression of inducible ventricular arrhythmias during electrophysiological study. This study examines the frequency and significance of concordance of these two approaches in the Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM) trial. Methods and Results Twenty-four-hour Holter monitoring was performed in patients randomized to the electrophysiology limb of the ESVEM study at the time of the first Drug trial and at the time of an effective Drug trial. Holter monitors were available in 65% (146/226) of patients at the time of the first Drug trial and in 93% (100/108) of patients at the time of an electrophysiology study predicting Drug Efficacy. There were no clinical differences between patients who had and those who did not have a Holter monitor. At the time of the first Drug trial, concordance of Holter and electrophysiological predictions of Drug Efficacy was observed in 46% of patients (both techniques predicted Efficacy in 23%; neither predicted Efficacy in 23%). Discordant results were observed in 54% (Holter suppression without electrophysiological suppression in 44%; electrophysiological suppression without Holter suppression in 10%). At the time of an electrophysiology study predicting Drug Efficacy, 68 of the 100 patients without inducible ventricular tachyarrhythmias also had suppression of spontaneous ventricular arrhythmias on the Holter recorded at the time of the electrophysiological study. Neither arrhythmia recurrence nor mortality was significantly different in patients with suppression of both inducible and spontaneous ventricular arrhythmias compared with those with only suppression of inducible arrhythmias. Comparison of patients with suppression of both inducible and spontaneous ventricular arrhythmias with the 188 patients in the Holter limb, in whom Efficacy was predicted by Holter monitoring only, revealed no difference in outcome. Conclusions In this population, (1) there is frequent discordance in prediction of Drug Efficacy and inEfficacy between electrophysiological study and Holter monitoring; (2) a requirement to fulfill both Holter and electrophysiological Efficacy criteria reduces the number of patients with an Efficacy prediction; and (3) suppression of both spontaneous ventricular ectopy and inducible ventricular tachyarrhythmias does not identify a group with better outcome.
Elizabeth A. Hahn - One of the best experts on this subject based on the ideXlab platform.
-
Effect of Reproducibility of Baseline Arrhythmia Induction on Drug Efficacy Predictions and Outcome in the Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM) Trial
The American journal of cardiology, 1997Co-Authors: David E. Mann, Elizabeth A. Hahn, Vernon Hartz, Michael J. ReiterAbstract:Spontaneous variability over time in the ease of induction of ventricular arrhythmias may mimic a Drug effect and affect the predictive value of Drug therapy guided by programmed stimulation. We assessed the effect of baseline reproducibility of arrhythmia induction on the incidence and accuracy of Drug Efficacy predictions in the Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM) trial. Patients with sustained ventricular tachyarrhythmias induced twice during baseline electrophysiologic testing with the same stimulation technique, i.e., induced at the same pacing site with the same drive cycle length and number of extrastimuli, were identified from the ESVEM database. These patients with highly reproducible arrhythmia induction were compared to those with less reproducible arrhythmias. Of 473 randomized patients with reproducibility data, 313 (66%) had highly reproducible arrhythmias. In patients randomized to electrophysiologic testing, baseline arrhythmia reproducibility did not affect the incidence of Drug Efficacy predictions (70 of 157 [45%], Drug Efficacy predictions in patients with highly reproducible arrhythmias vs 34 of 79 [43%] with less reproducible arrhythmias, p = 0.890). Drug Efficacy predictions obtained by electrophysiologic testing in patients with highly reproducible arrhythmias were not associated with decreases in arrhythmia recurrence (p = 0.202), all-cause mortality (p = 0.301), cardiac death (p = 0.358), or arrhythmic death (p = 0.307) compared to those with less reproducible arrhythmias. Analysis of patients with highly reproducible sustained monomorphic ventricular tachycardia led to similar results. In the ESVEM trial, most patients had highly reproducible arrhythmia induction during baseline electrophysiologic testing. Reproducibility of arrhythmia induction in the baseline state had no effect on the incidence or accuracy of Drug Efficacy predictions.
-
Reproducibility of Drug Efficacy Predictions by Holter Monitoring in the Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM) Trial
The American journal of cardiology, 1997Co-Authors: Michael J. Reiter, Labros A. Karagounis, David E. Mann, James A. Reiffel, Elizabeth A. Hahn, Vernon HartzAbstract:Selection of antiarrhythmic therapy may be based on suppression of spontaneous ventricular arrhythmias assessed by Holter monitoring, but the implications of discordant Holter results on repeat 24-hour monitoring has not been defined. This study examines the frequency and significance of reproducible Holter suppression on two 24-hour recordings in the Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM) trial. Repeat 24-hour Holter monitoring was obtained in patients randomized to the Holter monitor limb of the ESVEM trial, during the same hospitalization, after a Drug Efficacy prediction. These Holters were not used to define Drug Efficacy but were subsequently analyzed to determine the reproducibility of Drug Efficacy predictions by Holter monitoring. A repeat 24-hour Holter monitor, following the one that predicted Drug Efficacy, was available in 119 patients. Ninety-nine patients (83%) also had suppression that met Efficacy criteria on the second Holter monitor. There were no significant differences in arrhythmia recurrence (p = 0.612) or mortality (p = 0.638) in patients with concordant Holter results (n = 99; 1-year arrhythmia recurrence = 45%; 1-year mortality = 10%) compared with those with discordant Holter results (n = 20; 1-year arrhythmia recurrence = 45%; 1-year mortality = 16%). We conclude that (1) there is discordance between the first effective Holter monitor and a repeat Holter monitor in 17% of patients, and (2) suppression of ventricular ectopic activity on 2 separate 24-hour Holter monitors does not identify a group with a better outcome, nor does failure of suppression on the second Holter monitor identify a group with a worse prognosis.
Jozef Vercruysse - One of the best experts on this subject based on the ideXlab platform.
-
effect of sampling and diagnostic effort on the assessment of schistosomiasis and soil transmitted helminthiasis and Drug Efficacy a meta analysis of six Drug Efficacy trials and one epidemiological survey
Parasitology, 2014Co-Authors: Bruno Levecke, Jurg Utzinger, Stefanie Knopp, Simon Brooker, Russell J Stothard, Jose C Sousafigueiredo, Peter Steinmann, Jozef VercruysseAbstract:It is generally recommended to perform multiple stool examinations in order to improve the diagnostic accuracy when assessing the impact of mass Drug administration programmes to control human intestinal worm infections and determining Efficacy of the Drugs administered. However, the collection and diagnostic work-up of multiple stool samples increases costs and workload. It has been hypothesized that these increased efforts provide more accurate results when infection and Drug Efficacy are summarized by prevalence (proportion of subjects infected) and cure rate (CR, proportion of infected subjects that become egg-negative after Drug administration), respectively, but not when these indicators are expressed in terms of infection intensity and egg reduction rate (ERR). We performed a meta-analysis of six Drug Efficacy trials and one epidemiological survey. We compared prevalence and intensity of infection, CR and ERR based on collection of one or two stool samples that were processed with single or duplicate Kato-Katz thick smears. We found that the accuracy of prevalence estimates and CR was lowest with the minimal sampling effort, but that this was not the case for estimating infection intensity and ERR. Hence, a single Kato-Katz thick smear is sufficient for reporting infection intensity and ERR following Drug treatment.
-
field validity and feasibility of four techniques for the detection of trichuris in simians a model for monitoring Drug Efficacy in public health
PLOS Neglected Tropical Diseases, 2009Co-Authors: Bruno Levecke, Els Vandenhoute, Nathalie De Wilde, Jozef VercruysseAbstract:Background: Soil-transmitted helminths, such as Trichuris trichiura, are of major concern in public health. Current efforts to control these helminth infections involve periodic mass treatment in endemic areas. Since these large-scale interventions are likely to intensify, monitoring the Drug Efficacy will become indispensible. However, studies comparing detection techniques based on sensitivity, fecal egg counts (FEC), feasibility for mass diagnosis and Drug Efficacy estimates are scarce. Methodology/Principal Findings: In the present study, the ether-based concentration, the Parasep Solvent Free (SF), the McMaster and the FLOTAC techniques were compared based on both validity and feasibility for the detection of Trichuris eggs in 100 fecal samples of nonhuman primates. In addition, the Drug Efficacy estimates of quantitative techniques was examined using a statistical simulation. Trichuris eggs were found in 47% of the samples. FLOTAC was the most sensitive technique (100%), followed by the Parasep SF (83.0% [95% confidence interval (CI): 82.4-83.6%]) and the ether-based concentration technique (76.6% [ 95% CI: 75.8-77.3%]). McMaster was the least sensitive (61.7% [ 95% CI: 60.7-62.6%]) and failed to detect low FEC. The quantitative comparison revealed a positive correlation between the four techniques (Rs = 0.85-0.93; p < 0.0001). However, the ether-based concentration technique and the Parasep SF detected significantly fewer eggs than both the McMaster and the FLOTAC (p < 0.0083). Overall, the McMaster was the most feasible technique (3.9 min/sample for preparing, reading and cleaning of the apparatus), followed by the ether-based concentration technique (7.7 min/sample) and the FLOTAC (9.8 min/sample). Parasep SF was the least feasible (17.7 min/ sample). The simulation revealed that the sensitivity is less important for monitoring Drug Efficacy and that both FLOTAC and McMaster were reliable estimators. Conclusions/Significance: The results of this study demonstrated that McMaster is a promising technique when making use of FEC to monitor Drug Efficacy in Trichuris.
